Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial
October 18 2023 - 2:14AM
Dow Jones News
By Adria Calatayud
Roche Holding's Alecensa drug reduced the risk of disease
recurrence or death in a phase 3 trial for a type of non-small cell
lung cancer at an early stage, the company said Wednesday.
The Swiss pharmaceutical giant said a primary analysis of the
study results showed Alecensa reduced the risk of disease
recurrence or death by 76% compared with platinum-based
chemotherapy, demonstrating a statistically significant and
clinically meaningful improvement in disease-free survival.
The safety and tolerability of the drug in the trial were
consistent with previous studies and no unexpected safety findings
were observed, Roche said.
The company said it is conducting further analysis of overall
survival estimates given that data were immature at this stage.
Roche will submit data from the trial to global health
authorities, including the U.S. Food and Drug Administration and
the European Medicines Agency, it said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 18, 2023 01:59 ET (05:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024